Adenoviral delivery of an immunomodulatory protein to the tumor microenvironment controls tumor growth

Patrick O’Connell, Maja K. Blake, Yuliya Pepelyayeva, Sean Hyslop, Sarah Godbehere, Ariana M. Angarita, Cristiane Pereira-Hicks, Andrea Amalfitano, and Yasser A. Aldhamen

1Department of Microbiology and Molecular Genetics, College of Osteopathic Medicine, Michigan State University, 567 Wilson Road, 4194 Biomedical and Physical Sciences Building, East Lansing, MI 48824, USA; 2Department of Pediatrics, College of Osteopathic Medicine, Michigan State University, East Lansing, MI 48824, USA

Targeted modulation of the immune system against tumors can achieve responses in otherwise refractory cancers, which has spurred efforts aimed at optimizing such strategies. To this end, we have previously investigated cancer immunotherapy approaches using recombinant adenovirus vectors, as well as via modulation of the self-ligand receptor SLAMF7. Here, we present a novel approach for inducing adaptive immune responses in tumors at high concentrations via a recombinant adenoviral vector (Ad-SF7-Fc). Using multiple murine cancer models, we show that Ad-SF7-Fc can induce tumor control via augmentation of innate immunity; specifically, induction of type I interferons and activation of dendritic cells (DCs) and macrophages. Analogously, we find that modulating SLAMF7 signaling via an adenoviral vector expressing its intracellular adaptor, EAT-2, is also capable of inducing tumor control. Finally, we employ a novel in vivo prediction approach and dataset integration with machine learning to dissect how Ad-SF7-Fc modulates cell-type-specific responses in the tumor microenvironment to achieve tumor control. Thus, our novel combinatorial cancer immunotherapy highlights the benefit of multimodal immune modulation and lays a framework for combination with complementary approaches capable of inducing adaptive immune responses.

INTRODUCTION

Cancer immunotherapy has revolutionized the way we think about cancer from both treatment and research perspectives. Currently, the most clinically successful approaches to antagonize the immune system against tumors rely on the use of monoclonal antibodies which, for the most part, modulate T cell responses. While highly efficacious in subsets of patients with certain cancers, these antibodies still suffer a number of limitations, not limited to: their non-selective targeting of immune cells systemically, induction of autoimmunity, development of resistance, high production cost, and exaggerated adverse effects when used in combination. As an alternative approach to induce anti-cancer immune responses, recombinant viral vectors have been investigated, including a number of studies and clinical trials using human recombinant adenovirus vectors. These viral approaches function via multiple mechanisms including direct cytolysis of tumor cells and augmentation of anti-tumor immune responses, but have fallen short of the impressive responses produced by monoclonal antibodies. Combining antibody-based and viral-based approaches has the potential to address a number of the issues faced by these individual therapies.

The signaling lymphocytic activation molecule family member 7 (SLAMF7) (CRACC, CD319, CS-1) is a self-ligand receptor, restricted to hematopoietic cells and expressed at varying frequencies on different immune cell subsets. SLAMF7 is capable of mediating both activating and inhibitory signals in immune cells; a distinction largely dependent on the presence of its adaptor protein, Ewing’s sarcoma-associated transcript 2 (EAT-2). When SLAMF7 is activated in the presence of EAT-2, EAT-2 binds to SLAMF7’s phosphorylated intracellular immunoreceptor tyrosine-based switch motif (ITSM) and mediates immune cell activation, while in the absence of EAT-2, various inhibitory SH2 domain-containing phosphatases are recruited to SLAMF7’s ITSM. We recently demonstrated that SLAMF7 activation in type I interferon stimulated monocytes, which lack EAT-2, results in inhibition of pro-inflammatory chemokine responses. We also found that SLAMF7 signaling on CD8+ T cells reprograms them towards an exhausted phenotype, a finding of particular relevance to cancer immunotherapy. A number of studies have also described various roles for SLAMF7 on natural killer (NK) cell and dendritic cell (DC) activation/function that, considering how important functions of these two cell types are to tumor control, suggest therapeutically targeting SLAMF7 could affect anti-tumor immune responses.

Received 22 September 2021; accepted 4 December 2021; https://doi.org/10.1016/j.omto.2021.12.004.
Correspondence: Yasser Ali Aldhamen, PhD, Michigan State University, 567 Wilson Road, 4194 Biomedical and Physical Sciences Building, East Lansing, MI 48824, USA
E-mail: aldhamen@msu.edu
Extending these findings, we recently demonstrated that targeting SLAMF7 using a SLAMF7-Fc (CRACC-Fc, SF7-Fc) fusion protein enhances natural killer cell (NK) cell and DC activation. Therefore, we hypothesized that a recombinant adenovirus vector-expressing SLAMF7-Fc (Ad-SF7-Fc) may augment anti-tumor responses via localized immune activation from both the adenovirus vector and SLAMF7-Fc, while delivering high levels of SLAMF7-Fc to the tumor microenvironment (TME) in a targeted, cost-effective manner. Through testing Ad-SF7-Fc across multiple murine cancer models, we found this integrated immunotherapy capable of augmenting innate immune responses and concordantly controlling tumor growth. Novel in vivo prediction approaches confirm Ad-SF7-Fc can enhance pro-inflammatory DC responses and suggest that SLAMF7 activation on plasmacytoid DCs (pDCs) may be particularly efficacious in inducing anti-tumor immunity. Finally, we use a machine learning-based approach to identify the factors critical to tumor control by Ad-SF7-Fc.

RESULTS

Ad-SF7-Fc induces high expression of SF7-Fc and activates the innate immune system

While we found that our SF7-Fc fusion protein was able to modulate SLAMF7 signaling and induce innate immune activation, the production of large amounts of recombinant proteins like SF7-Fc is expensive and delivery to specific locations challenging. To address this, we constructed a recombinant, replication deficient adenovirus vector capable of expressing SF7-Fc (Ad-SF7-Fc). We first confirmed the ability of Ad-SF7-Fc to express SF7-Fc by infecting HEK293 cells (Figure 1A).

Previously, we found co-administration of SF7-Fc fusion protein and Ad-null increased IFNγ production by NK cells. Here, we found that treatment with Ad-SF7-Fc increased IFNγ production and CD69 expression on NK cells compared with the Ad-null control (Figures 1B and 1C). Since we also found that SF7-Fc is capable of activating DCs, we further investigated DC responses after treatment with Ad-SF7-Fc. We observed increased DC maturation as evidenced by increased CD86 (Figure 1D) and CCR7 (Figure 1E) expression on DCs, along with increased CD86 expression on macrophages (Figure 1F). Additionally, Ad-SF7-Fc was able to augment immune cell activation on B cells, CD8+ T cells, and CD4+ T cells (Figures S1A–S1C).

Ad-SF7-Fc augments cytokine and type I interferon responses

To investigate the impact of Ad-SF7-Fc on cytokine responses, we evaluated splenic gene expression in mice 6 h after vector injection. We found up-regulation of Il12, Csf2 (GM-CSF), and Il6 (Figure 2A). Interestingly, Ad-SF7-Fc decreased expression of Cxcl10 (IP-10) compared with Ad-null (Figure 2A), suggesting SF7-Fc may be activating SLAMF7 on monocytes; a result consistent with our previous work. Since NK cell activation is mediated by type I interferons and we previously found that SLAMF7 is both an IFN responsive gene and modulator of specific IFN responses, we investigated if Ad-SF7-Fc could augment type I IFN responses. In comparison

Figure 1. Ad-SF7-Fc expresses SF7-Fc and activates NK cells and DCs

(A) HEK-293-C7 cells (n = 3) were control treated with PBS (naive) or infected at an MOI of 1 × 10^2 with Ad-null or Ad-SF7-Fc overnight and SLAMF7 gene expression was assessed. BALB/c mice were injected I.V. with 1 × 10^10 v.p. of Ad-null (n = 6), Ad-SF7-Fc (n = 6), or not injected (naive, n = 3), spleens were harvested 10 h later and immune cell phenotype was analyzed by flow cytometry. (B) IFNγ production by NK cells. (C) CD69 expression on NK cells. (D) CD86 expression on DCs. (E) CCR7 expression on cDCs. (F) CD86 expression on macrophages. All data presented as mean ± standard error of the mean and representative of a single experiment. Groups compared with one-way ANOVA with Tukey’s multiple comparison test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s. = not significant.
with Ad-null-treated mice, we detected increased expression of *Ifna*, *Ifnb*, *Isg15*, and *Oas2* in Ad-SF7-Fc-treated mice (Figure 2A). Furthermore, we detected increased IL-12(p40) and MIP-1β (CCL4) proteins in the plasma of Ad-SF7-Fc-treated mice compared with Ad-null-treated controls (Figure 2B).

**Ad-SF7-Fc controls CT26 tumor growth in the absence of humoral immune responses**

To examine whether Ad-SF7-Fc induces anti-tumor responses in vivo we used the CT26 mouse model. We first confirmed successful expression of SF7-Fc in CT26 cells in vitro (Figures 3A and S3A) and in vivo (Figure 3B). Then, we treated established CT26 tumors intra-tumorally (I.T.) with Ad-null, Ad-SF7-Fc, or untreated (naive). We found significantly increased survival in Ad-SF7-Fc treated mice (Figure 3C) and decreased tumor volume in Ad-SF7-Fc treated as compared with Ad-null treated tumors (Figure 3D).

To determine whether the tumor control we observed was due to an increased adaptive immune response, we investigated if an abscopal effect \(^{17}\) was present in our CT26 model. To explore whether Ad-SF7-Fc could induce an abscopal effect we implanted two CT26 tumors in the hind flanks of mice and treated one side twice with Ad-null or Ad-SF7-Fc (Figures 3D and 3E). We not only found superior tumor control in tumors directly injected with Ad-SF7-Fc (Figure 3D), but also noted that the contralateral tumors in mice receiving Ad-SF7-Fc had superior tumor control compared with mice receiving Ad-null (Figure 3E). This indicates that an abscopal effect is present in mice treated with Ad-SF7-Fc. These data also suggest that the modulation of SLAMF7 functions by Ad-SF7-Fc induces a memory immune response against CT26 tumors. We also assessed tumor antigen-specific B cell memory responses to determine if the adaptive response was humoral in nature. Mice were co-vaccinated with various adenovirus vectors and CT26 tumor lysate. We found Ad-SF7-Fc/CT26 lysate co-vaccinated mice produced only slightly higher levels of CT26-specific antibodies compared with Ad-null/CT26 lysate (Figure S3B). To measure the functionality of these antibodies, we performed antibody-dependent cellular cytotoxicity (ADCC) assays using plasma from the vaccinated mice, carboxyfluorescein succinimidyl ester (CFSE)-labeled CT26 cells, and either total splenocytes (Figure 3F) or isolated NK cells (Figure 3G). We found no significant difference between cultures using
plasma from Ad-SF7-Fc-vaccinated mice versus Ad-null-vaccinated mice (Figures 3F and 3G). To determine if Ad-SF7-Fc triggers NK and T cell infiltration into CT26 tumors, we performed immunohistochemistry and found a moderate increase in CD3+ T cells and DX5+ NK cells in mice vaccinated with Ad-SF7-Fc/CT26 lysate in comparison with Ad-null (Figure 3H). Since only expression of DX5 was used to identify NK cells, it is possible minor populations of other DX5+ lymphocytes were counted as well. Altogether, this suggests that Ad-SF7-Fc is capable of generating a memory immune response in the CT26 model, but that this response is not humoral in nature, implying that it is cell mediated.

Ad-SF7-Fc controls B16-F10 tumor growth without modulating T cell exhaustion or remodeling the TME

Since we found that Ad-SF7-Fc augments Th1 cytokine/chemokine responses, and because it is known that BALB/c mice have Th2 skewed immune responses, we reasoned that Ad-SF7-Fc may function better in the B16-F10 tumor model in C57BL/6 mice. We first confirmed that our recombinant Ad5 viruses could infect B16 cells (Figure S3A). Assessing the impact of SF7-Fc overexpression in the TME, we found significantly reduced tumor volumes and improved survival in B16 tumors treated with Ad-SF7-Fc in comparison with the Ad-null-treated controls (Figures 4A and 4B). Considering we recently discovered that SLAMF7 signaling on CD8+ T cells reprograms them toward exhaustion,10 we assessed the exhaustion status of CD8+ tumor-infiltrating lymphocytes (TILs) from B16 tumors. We found no significant changes in the frequency of ToxhighPD-1high exhausted CD8+ TILs, nor any surface markers of T cell exhaustion, or proliferation in Ad-SF7-Fc-treated tumors (Figures 4C–4F and S4A–S4D). Furthermore, we found no changes in the same markers on CD4+ TILs (Figures S4E–S4I). After reconstructing the exhaustion developmental trajectory in CD8+ TILs,10,19 we found that Ad-SF7-Fc does not impact progression through this trajectory (Figure 4G).
We also profiled the immune TME of these mice using high dimensional single-cell spectral cytometry. Unbiased clustering revealed 11 distinct immune cell subsets (Figure 4H), each displaying expected marker expression patterns (Figure 4I). The frequency of each cell subset did not significantly change between Ad-SF7-Fc-treated and Ad-null-treated B16 tumors (Figure 4J), suggesting that Ad-SF7-Fc does not globally remodel the TME.

Figure 4. Ad-SF7-Fc controls B16 tumor growth without affecting T cell exhaustion or remodeling the TME

(A) C57BL/6 mice were inoculated with $4 \times 10^5$ B16-F10 cells and on day seven were treated I.T. with $1 \times 10^{10}$ v.p. of either Ad-null or Ad-SF7-Fc. (B) Kaplan-Meier survival curve of virus treated mice. TILs from virus treated B16 tumors were isolated on day 18 and the frequency of TOX$^{\text{high}}$,PD-1$^{\text{high}}$, CD8$^+$ T cells (C), LAG3$^+$ CD8$^+$ T cells (D), 2B4$^+$ CD8$^+$ T cells (E), and CD38$^+$ CD8$^+$ T cells (F) was assessed. (G) The exhaustion developmental trajectory (assessed by co-expression of SLAMF6 and CD69) of CD8$^+$ TILs was compared between Ad-null and Ad-SF7-Fc treated tumors. (H) Tumor infiltrating immune cells from Ad-null and Ad-SF7-Fc treated B16 tumors were assessed by high dimensional single-cell spectral cytometry. FlowSOM-generated clusters were displayed on a UMAP dimensionally reduction plot. (I) Marker expression across all clusters in (H). (J) Frequency of each immune cell subset from (H and I) compared across Ad-null and Ad-SF7-Fc-treated B16 tumors. Data in (A and G) presented as mean ± standard error of the mean. The log rank test was used to compare groups in (B). Two-way ANOVA with Tukey’s multiple comparison test used to compare groups in (A and G). Unpaired, two-tailed t test used to compare groups in (C–F). A generalized linear mixed model was used to compare groups in (J). All data representative of two independent experiments showing similar results. **p < 0.01; ****p < 0.0001; n.s. not significant. AF = autofluorescence.

SLAMF7 expression across the TME and tumor-infiltrating myeloid cell phenotypes in Ad-SF7-Fc-treated mice

We next wanted to identify which cell types in the TME express SLAMF7, and thus might be modulated by our Ad-SF7-Fc vector. Using B16 tumor-bearing SLAMF7-deficient (SLAMF7$^{-/-}$) mice treated with Ad-null, we determined SLAMF7 expression across the TME (Figure 5A). Because we previously found that Ad-SF7-Fc was able to induce DC activation (Figure 1D) and IL-12 production (Figures 2A and 2B), we wished to further investigate tumor-infiltrating DC phenotypes in our B16 model. We identified seven distinct DC subsets (Figures 5B and 5C). We also included markers in our panel allowing the identification of the recently described mature regulatory dendritic cell (mregDC) subset and found that our panel was capable of efficiently identifying mature regulatory dendritic cells in an unbiased manner (Figures 5B, 5C, and 55A). Additionally, we identified high co-expression of SLAMF7 and CD38 on the DC1 B subset (Figure 5D), which was intriguing, because we recently identified a pathogenic subset of Tumor-associated macrophages (TAMs) in clear cell renal cell carcinoma (ccRCC) co-expressing the same markers. Through a
comparison of frequencies of DC subsets across Ad-SF7-Fc-treated mice responding or not responding to treatment, we noted that responding mice had more of the DC1 B subset, suggesting that, in contrast to TAMs, DCs co-expressing these markers might be anti-tumorigenic (Figure 5E). This is not surprising; DCs are known to express EAT-2,21 suggesting that SLAMF7 activation in these cells induces IL-12 and pro-inflammatory responses. Supporting this, we found higher expression of IL-12 and other pro-inflammatory cytokines in the tumors of Ad-SF7-Fc treated B16 tumors in comparison to Ad-null (Figure 5F).

We investigated TAM heterogeneity in our model and identified nine TAM subsets (Figures 5G and 5H). We found a SLAMF7highCD38high TAM subset similar to the one we previously identified in patients with ccRCC,10 suggesting this subset may be conserved across tumors and species (Figures 5G and 5H). However, Ad-SF7-Fc treatment did not alter the frequency of this subset (Figure S5C). Interestingly, we found that TAM subsets expressing SLAMF7 also co-expressed programmed death ligand 1 (PD-L1), with a correlation of 0.6 (Figures 5I and S5B). We extended this analysis across the TME and found it to be conserved across myeloid cells, except for pDCs and neutrophils (Figure 5J).

**EAT-2 expression in tumor-infiltrating innate immune cells identifies mice able to control B16 tumors**

As the presence of EAT-2 determines whether SLAMF7 functions as an activating or inhibitory receptor,11 we examined EAT-2 expression in tumor-infiltrating immune cells in our B16 model. While we found that treatment with Ad-SF7-Fc did not change EAT-2 levels in NK cells or DCs in comparison with Ad-null (data not shown), we found that B16 tumors responding to adenovirus treatment had significantly higher expression of EAT-2 in NK cells (Figure 6A), cDC2 cells (Figure 6B), and cDC1 cells (Figure 6C). To determine if increased EAT-2 expression controls tumor growth, we treated CT26 tumors I.T. with our previously described...
that modulating SLAMF7 signaling via EAT-2 enhances the pro-inflammatory activity of tumor-infiltrating innate immune cells, and thus results in better tumor control.

Cell type-specific, single-cell predictions of the function of Ad-SF7-Fc in vivo

Because SLAMF7 is a homotypic receptor, and since SF7-Fc is composed of the extracellular domain of SLAMF7, SF7-Fc can conceivably function to both activate and/or block SLAMF7 signaling, depending on local environmental factors and the cell type in question. Additionally, activating or blocking SLAMF7 can have vastly different outcomes on different cell types depending on the presence of EAT-2,9,11 which may mechanistically explain how Ad-SF7-Fc achieves tumor control. Therefore, we devised an approach using high dimensional spectral cytometry, which allowed us to predict if SF7-Fc was activating or blocking SLAMF7 at the single-cell level (Figure 7A; see materials and methods). We found that Ad-SF7-Fc was primarily activating DCs and monocytes, having equally opposing effects on TAMs and CD8+ T cells, and primarily blocking pDCs and NK cells (Figures 7B–7F, S6C, and S6D). We next calculated the ratio of SLAMF7 activation versus blocking on each cell type between mice responding to Ad-SF7-Fc or not, and found that responding mice had considerably more pDC activation (Figure 7G).

Alterations in the immune TME in SLAMF7/−/− mice

We also compared immune cell subsets between Ad-null-treated wild-type (WT) and Ad-null-treated SLAMF7/−/− mice used for prediction analyses. We detected decreased levels of NK and CD8+ T cells in the TME of SLAMF7/−/− mice (Figure S6E); the latter is consistent with our previous work.10 We also investigated TAM subsets in these mice and found a dramatic re-structuring of the TAM landscape in SLAMF7/−/− mice (Figures S6F and S6G). Finally, we identified all markers on all cell subsets statistically different between WT and SLAMF7/−/− mice and found decreased PD-1 and increased PD-L1 on NK cells (Figure 7H). Together, these findings highlight the broad and diverse roles of SLAMF7 signaling in the TME.

Immunological elastic net identifies features underlying tumor response to Ad-SF7-Fc

To determine why some tumors respond with an attenuation of growth to Ad-SF7-Fc and others do not, we employed a machine learning-based approach using the recently described immunological elastic net (iEN) algorithm.23 Into iEN, we input multiple datasets representing a host of systemic and tumor-localized immune measurements, and a table of immune-specific priors (Figure 8A and Table S1; see materials and methods). We validated that our iEN model can discriminate responders from non-responders, and that the addition of our priors improves model performance (Figures 8B and 8C). To determine the factors allowing iEN to identify responders, we generated and performed a network analysis (See materials and methods), which showed clustering of common immune archetypes (Figure 8D). Coloring features on the network by those which were increased or decreased in responding B16
tumors, we found many expected changes in responding tumors like: increased CD8+ T cells, more Texprog1 CD8+ T cells, increased intra-tumoral IFNγ, fewer neutrophils (myeloid-derived suppressor cells), fewer TAMs, and less CD206 expression TAMs (Figure 8E and Table S2). Critically, we found a number of features supporting the ability of SLAMF7 signaling to modulate tumor control, buttressing our hypothesis that Ad-SF7-Fc functions to control tumor growth via DC and innate immune cell stimulation. The iEN found increased levels of IL-12(p40) in responding tumors and increased SLAMF7 on TAMs and DCs from responding tumors (Figure 8E and Table S2). iEN also found that higher predicted activation of SLAMF7 on TAMs was important in separating responders that, paired with our earlier data showing high co-expression of SLAMF7 and PD-L1 on TAMs, suggests that SLAMF7 may be able to modulate this immune suppressive pathway to achieve tumor control (Figure 8E and Table S2). It should be noted that our model generated by iEN is specific to our experimental setup and is not generalizable across tumor models or other therapeutic modalities.

SLAMF7 modulation of this pathway is likely one mechanism by which Ad-SF7-Fc achieves tumor control. Complementing this IL-12 response is the induction of type I IFN by Ad-SF7-Fc. Type I IFN responses can be beneficial in tumor control and achieve this via multiple mechanisms. Indeed, previous studies have found that IL-12 and type I IFNs can synergize to induce potent immune activation, and there is much interest in combination cancer immunotherapies involving IL-12. Since pDCs are one of the primary producers of type I IFNs, express SLAMF7 in the TME, and express EAT-2 (www.immgen.org), it is plausible that SLAMF7 activation on intratumoral pDCs drives pDC production of type I IFNs.

Our discovery that Ad-SF7-Fc does not modulate T cell exhaustion in the TME or significantly increase humoral immune responses against tumors was unexpected based on our previous work. However, there are a number of explanations for this, including the use of an adenoviral vector to deliver SF7-Fc, contributions from the TME itself, and the potential for SF7-Fc to both block and activate SLAMF7 simultaneously. The latter we worked to address using our novel
in vivo prediction approach, which yielded results consistent with our other studies showing that SF7-Fc activates DCs. Our approach also found that B16 tumors responding to Ad-SF7-Fc had more SLAMF7 activation on pDCs, which corresponds with increased type I IFN production by Ad-SF7-Fc. Since Ad-SF7-Fc does seem to both activate and block SLAMF7 on the same cell subsets, our results suggest that targeting SLAMF7 modulation to particular immune cell types could prove more effective. Importantly, while our results showing Ad-SF7-Fc can induce an abscopal effect (presumably via induction of an adaptive immune response), and that this effect is likely due to augmentation of cell-mediated immunity (T cell responses), we did not directly investigate this and only ruled out augmentation of the humoral arm of the adaptive immune response.

Our studies using SLAMF7<sup>−/−</sup> mice have yielded a number of insights into the role of SLAMF7 in the TME. Among these is the decreased frequency of NK and CD8<sup>+</sup> T cells in the TME of SLAMF7<sup>−/−</sup> mice, which is consistent with our previous work. This finding provides evidence that SLAMF7 may function as an adhesion molecule important for lymphocyte egress and residency in the TME. Discovering that tumor-infiltrating NK cells from SLAMF7<sup>−/−</sup> mice do not express PD-1 in contrast to WT mice is particularly interesting given that we recently found SLAMF7 signaling on T cells is able to modulate PD-1 expression. This suggests a similar mechanism may be present in NK cells and may contribute to tumor control as PD-1 signaling is inhibitory on NK cells. Analogously, we found increased PD-L1 expression on NK cells from SLAMF7<sup>−/−</sup> mice, supporting potentially linked roles for SLAMF7 in the regulation of PD-1/PD-L1 receptor pair.

Perhaps our most interesting observation was the strong co-expression of SLAMF7 and PD-L1 on tumor-infiltrating myeloid cells that we observed. Of the myeloid cell types expressing SLAMF7,
DCs had the lowest co-expression of SLAMF7 with PD-L1, which may be due to the fact that these cells express EAT-2, whereas the other subsets do not. The high co-expression of these two markers may also explain our previous findings that a subset of SLAMF7<sup>high</sup>CD38<sup>high</sup> TAMs was linked to poor survival in ccRCC, since these cells have higher PD-L1 expression than other TAM subsets (data not shown).<sup>10,15</sup> The theory that SLAMF7 may be able to modulate PD-L1 expression on TAMs (or other myeloid cell types) is supported by results from our machine learning analysis of responses to Ad-SF7-Fc. Here, we found that responders counterintuitively had higher expression of PD-L1 on TAMs, but also had more SLAMF7 on TAMs and critically, more predicted SLAMF7 activation on TAMs. Taken together, this implies that either modulation of SLAMF7 with SF7-Fc induces anti-tumor responses in TAMs, or the strong innate immune response of Ad-SF7-Fc is capable of overcoming coincidentally induced pro-tumor TAM responses.

By combining modulation of SLAMF7 signaling with delivery and immune stimulation via a recombinant adenovirus vector, we provide proof-of-concept that such an approach can achieve superior tumor control compared with an empty viral vector. While our approach functions primarily by augmentation of the innate immune system, future derivations of this paradigm capable of inducing pan-adaptive immune responses should prove highly effective as a cancer immunotherapeutic strategy.

**MATERIALS AND METHODS**

**Adenovirus vector construction**

All adenovirus used in this study are of human serotype 5. Ad-null was constructed and purified as previously described.<sup>16</sup> Ad-SF7-Fc was constructed and purified in a similar manner, where the SLAMF7 extracellular domain fused to mlgG1-Fc (SLAMF7/mlgG-Fc) (NCBI Reference Sequence: NM_144539.5) was excised using primers flanked by EcoRI and HindIII restriction endonucleases (NEB) from a plasmid (Biomatik) and sub-cloned into the pShuttle vector, containing a CMV expression cassette. The resulting pShuttle-SF7-Fc plasmid was linearized with Pmel restriction enzyme and homologously recombined with the pAdEasy1 Ad vector genome yielding Ad-SF7-Fc. HEK293 cells were transfected with Pmel linearized plasmid and viable virus was obtained and amplified after several rounds of expanding infection. Ad-SF7-Fc virus was purified using a CsCl<sub>2</sub> gradient. The number of viral particles was quantified using optical density measurement at 260 nm, as previously described.14 All viruses were found to be replication incompetent (RCA free) by both RCA polymerase chain reaction (PCR) (E1 region amplification) and direct sequencing methods, as described previously.<sup>14,22</sup>

**Tumor models**

All animal procedures were approved by the Michigan State University Institutional Animal Care and Use Committee (http://iacuc.msu.edu/). SLAMF7<sup>−/−</sup> mice were generated as previously described.<sup>15</sup> CT26 model: 8-week-old male BALB/c mice were injected subcutaneously (S.Q.) in the flank with 1.5 × 10<sup>6</sup> CT26.CL25 (ATCC, CRL-2639) cells in 100 µL of phosphate-buffered saline (PBS). Eight days later, once visible tumors formed, mice were split randomly into three groups and were either injected I.T. with 10<sup>10</sup> viral particles (v.p.) of Ad-null (n = 15), Ad-SF7-Fc (n = 15), or not injected (n = 14). Mice were monitored every 2 to 3 days and their tumor size was assessed with calipers. Tumor size was calculated with the following formula: 0.5 × (Length × Width<sup>2</sup>). In studies where tumors were placed on both hind flanks, one-half as many cells were injected into each flank at the same time. Mice where a tumor never formed were not included in analysis. B16-F10 model: 4 × 10<sup>5</sup> B16 tumor cells were injected into the hind flanks of 8- to 12-week-old male C57BL/6j mice as previously described.<sup>15</sup> At day 7 after tumor implantation I.T. injection of Ad-null or Ad-SF7-Fc (n = 7-12 per treatment) was performed using 10<sup>10</sup> v.p. of respective virus.

**Cell culture**

CT26 and B16-F10 tumor cell lines were cultured in modified RPMI-1640 media (ATCC, 30-2001) supplemented with 10% heat inactivated fetal bovine serum (FBS), and 1× penicillin, streptomycin and fungizone (PSF) (Invitrogen). HEK-293C7 cells were cultured in DMEM media, supplemented with 10% FBS, 1× PSF, and hygromycin.

ADCC assays were performed as described previously.<sup>37</sup> Briefly, CFSE-stained CT26 cells were plated at 1 × 10<sup>5</sup> cells/well in U-bottom 96-well cell culture plates. Total splenocytes from naive mice were incubated with CFSE-CT26 cells (20:1 Effector:Target) and cultured for 18 h in presence of plasma (1:200 dilution) from Ad-null/CT26 lysate, Ad-SF7-Fc/CT26 lysate vaccinated, or non-vaccinated mice. Alternatively they were cultured with Dx5+ NK cells isolated via magnetic beads (Miltenyi kit: 130-052-501) from naive mice and incubated with CFSE-CT26 cells (1:1 E:T ratio) overnight in presence of plasma (1:50 dilution) from vaccinated mice. Cultures contained 2 ng/mL of murine IL-2 (R&D). Tryptsined cells were stained with a viability dye and analyzed by flow cytometry on a BD LSR II cytometer.

**Vaccination studies**

Six-week-old BALB/c male mice were injected twice intramuscularly (n = 6) over a period of 1 month (days 0 and 12) with 200 µg of CT26 tumor lysate, tumor lysate + 10<sup>10</sup> v.p./mouse of Ad-null, tumor lysate + 10<sup>10</sup> v.p./mouse of Ad-SF7-Fc, or not injected (naive, n = 4). On day 27, mice were sacrificed, tumors were harvested, and immunohistochemistry (IHC) was performed.

**Tumor lysate preparation**

Tumor lysates were prepared using five freeze-thaw cycles, followed by sonication and centrifugation as described previously.<sup>38</sup> Sample concentration was determined using BCA protein kit (Sigma-Aldrich) per manufacturer’s protocol and as previously described,<sup>39</sup> after which the samples were stored at −80°C until use.

**Innate immune study**

Six-week-old BALB/c male mice were injected I.V. with 10<sup>10</sup> v.p. of Ad-null (n = 6), Ad-SF7-Fc (n = 6), or not injected, naive (n = 3).
After 10 h, plasma and spleens were collected for Bioplex and flow cytometry analysis.

**Flow cytometry and spectral cytometry**
Cells were prepared and stained as previously described.  All antibodies used are listed in (Table S3). Intracellular staining was performed with the Cytofix/Perm kit (BD Biosciences) per the manufacturer’s instructions. Viability staining was performed with Zombie NIR Fixable Viability dye (BioLegend). Fc receptors were blocked in all samples during staining with mouse Fc block (BD Biosciences). When staining cells from B16 tumors, BD Brilliant Stain buffer (cat: 563794) was used per the manufacturer’s instruction. Samples were collected on either a five-laser Cytek Aurora Spectral Cytometer or a three-laser BD LSR II cytometer and data were analyzed using FlowJo version 10.6.1 (Tree Star) and/or R. All gating schemes can be found in (Figure S2). High dimensional single-cell spectral cytometry was performed in R by first cleaning up the data in FlowJo (Figure S2). Data were exported from FlowJo as FCS files, which were then loaded into R. The CATALYST package was used to perform all analyses with a cell annotation and dimensionality reduction approach as previously described. An arcsinh transformation of 6000 was used for all spectral cytometry data. Analysis was performed on cells pooled from all conditions as previously described.

**Cytokine and chemokine analysis**
Mouse 23-analyte multiplex-based assay was used to determine cytokine/chemokine concentrations via Luminex 100 per manufacturer’s protocol (Bio-Rad), as previously described. Plasma was used at 1:4 dilution and 500 µg of tumor lysate was assessed.

**ELISA analysis**
Six-week-old BALB/c male mice were given three doses of 200 µg of CT26 tumor lysate and 10⁶ v.p. of Ad-null or Ad-SF7-Fc intraperitoneally over a period of 5 weeks, at which point they were injected with 2.5 x 10⁶ CT26 tumor cells. At 41 days after the tumor challenge, plasma from Ad-null (n = 6), Ad-SF7-Fc (n = 7), and naive (n = 2) mice was collected. ELISA assessing levels of CT26-specific antibodies in the plasma was assessed as described previously, where 100 µg of CT26 lysate was plated per well in a high-binding 96-well plate (Corning), incubated at 4°C overnight, and plasma was plated at 1:100, 1:200, and 1:500 dilutions.

**Quantitative RT-PCR**
Six-week-old BALB/c male mice were injected I.V. with 10⁹ v.p. of Ad-null (n = 6), Ad-SF7-Fc (n = 6) or not injected, naive (n = 3). 6 h later, spleens were harvested and snap frozen in liquid nitrogen. RNA was extracted using Trizol reagent (Life Technologies), per manufacturer’s protocol. cDNA was generated using SuperStrand First Strand Synthesis Kit III (Invitrogen) from Trizol-isolated RNA per the manufacturer’s protocol. Quantitative RT-PCR was performed using SYBR green PCR Mastermix (Life Technologies) and analyzed on a QuantStudio7 system (Thermofisher). The following primers were used: Isg15: For: 5’GGTGTCCGTGACTAACCCTAC-3’, Rev: 5’TGGAAAGGGTAAACGGGTCTCCT’; Oas2: For: 5’TGGAAGGATACATCGGGAAGG-3’, Rev: 5’GGTCTCGATTACCTGCACTT-3’; Ilfna: For: 5’GCCTGTACCTCCTTGATACAAT-3’, Rev: 5’CAGCAGTCATTGCCAGGAAAGC-3’; Ifnb: For: 5’TGGTGGAAATGAGACATTTGTG-3’, Rev: 5’CTCCCA CGTCAATTCTTCTCCT-3’; Il6: For: 5’TGGTGTGCTGGATCTTCTGCT-3’, Rev: 5’ACAGAGGTTCAA CGTGTCTTCT-3’; csf2: For: 5’GGCTTTGGAAGCATGAGGGG-3’, Rev: 5’GGAGAAACTGTTAGAGAGGACTT-3’; mGapdh: For: 5’AG AACATCATCCCTGCATCC-3’, Rev: 5’CACATTGGGTTAGGA CAC-3’.

HEK-293-C7 cells were plated at 2x10⁶ cells/mL in 12-well plates in 500 µL of complete RPMI media. Ad-null and Ad-SF7-Fc viruses were added at multiplicity of infection (MOI) of 10⁴ v.p./cell. Mock treated cells were treated with PBS. After 12 h, RNA was extracted using Trizol. Primers used: Slamf7: For: 5’GGCACATGGTGATCAATCT-3’, Rev: 5’ATCGCAAGGGATACATCAGA-3’; hGapdh: For: 5’GGGATGTGAAACCTGAGGATG-3’, Rev: 5’GCCATCACGTCCTTGAGGG-3’. The ΔΔCt method was used to compare gene expression across conditions and all genes were normalized to GAPDH in all experiments.

**Immunohistochemistry**
Samples were fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned on a rotary microtome at 4 µm. Sections were placed on positively charged slides and dried at 56°C overnight. After deparaffinization in Xylene, slides underwent heat-induced epitope retrieval in a steamer using Scytek Citrate Plus Retrieval pH 6.0 followed by several rinses in distilled water. Endogenous Peroxidase was blocked via a 3% Hydrogen Peroxide/Methanol bath for 30 min. After blocking for non-specific protein with Rodent Block M (Biocare) for 10 or 20 min, sections were incubated with appropriate primary antibodies as described in (Table S4). Micro-Polymer (Biocare) reagents were subsequently applied for specified incubations followed by reaction development with Romulin AEC (Biocare) and counterstained with cat hematoxylin. The number of positive cells was manually counted under magnification 10x for CD3-stained, 20x for CD8-stained, and 40x for DX5-stained slides, where five areas per sample, and at least two sections per sample were used.

**Intra-tumor immune cell isolation**
Tumors were surgically removed from mice and placed in ice-cold PBS. Tumors were minced and non-tumor tissue was removed. Cell suspension was pelleted and resuspended in RPMI with 0.5 mg/mL Collagenase IV (Millipore-Sigma) and 1 x 10² IU/mL DNaseI (Millipore-Sigma) under constant, gentle agitation at 37°C for 1 h. Digestion was stopped with EDTA and RPMI-1640 supplemented with 10% FBS and cell suspension was filtered through a 40µm cell strainer. Cells were then subject to a Ficoll-Plaque centrifugation step to enrich for immune cells.

---

**Table S3**
- **Isg15**: For: 5’GGTGTCCGTGACTAACCCTAC-3’, Rev: 5’TGGAAAGGGTAAACGGGTCTCCT’
- **Oas2**: For: 5’TGGAAGGATACATCGGGAAGG-3’, Rev: 5’GGTCTCGATTACCTGCACTT-3’
- **Ilfna**: For: 5’GCCTGTACCTCCTTGATACAAT-3’, Rev: 5’CAGCAGTCATTGCCAGGAAAGC-3’
- **Ifnb**: For: 5’TGGTGGAAATGAGACATTTGTG-3’, Rev: 5’CTCCCA CGTCAATTCTTCTCCT-3’
- **Il6**: For: 5’TGGTGTGCTGGATCTTCTGCT-3’, Rev: 5’ACAGAGGTTCAA CGTGTCTTCT-3’
- **csf2**: For: 5’GGCTTTGGAAGCATGAGGGG-3’, Rev: 5’GGAGAAACTGTTAGAGAGGACTT-3’
- **mGapdh**: For: 5’AG AACATCATCCCTGCATCC-3’, Rev: 5’CACATTGGGTTAGGA CAC-3’.
SLAMF7 activating and blocking predictions

24 h after a second I.T. injection of Ad-null or Ad-SF7-Fc, the tumors were harvested, cells were stained, and analyzed on a Cytek Aurora spectral cytometer, all as described above. We also confirmed that acute administration of adenovirus does not remodel the TME (Figure S6B). Cells were clustered and annotated as described above. To perform predictions, first we obtained a signature for what a cell with SLAMF7 signaling looks like. To get this, we first subsetted to just a single immune cell type, calculated the median expression of each marker in that cell type in WT (Ad-null treated) and SLAMF7+/− (Ad-null treated), and subtract the SLAMF7+/− marker expression values from WT. We then selected the markers with the most positive and most negative difference to use as a signature. This was done via manual inspection and typically the top three to four and bottom four to five markers were chosen. Markers that would never be expected to be expressed on a particular cell type were excluded. This yielded a SLAMF7 signature of both up-regulated and down-regulated markers on a cell-type-specific basis.

We then subsetted the same cell type from WT (Ad-SF7-Fc treated) mice and used the previously calculated signature to generate a SLAMF7_score for each cell. The score was calculated using a previously published formula used to obtain signature scores from scRNA-seq data. Importantly, our prior work demonstrated that activation of SLAMF7 with SF7-Fc leads to its down-regulation, and we confirmed that blocking SLAMF7 with SF7-Fc leads to its up-regulation (Figure S6A). Therefore, for each cell type we plotted the SLAMF7_score by SLAMF7 expression as a dot plot and expected that cells where SLAMF7 is being blocked should have high SLAMF7 expression (Figure S6A) and a low SLAMF7_score, while cells where SLAMF7 is being activated should have low SLAMF7 expression and a high SLAMF7_score. Cells where SLAMF7 is being activated or inhibited naturally come off the diagonals so we selected the cells at either extreme of the appropriate diagonals as being blocked or activated.

To calculate outliers in an unbiased manner we identified the points on the plot representing the intersection of the 25th percentile of SLAMF7 expression and the 75th percentile of SLAMF7_score for defining the boundary of cells getting SLAMF7 blocked. We did the reverse for cells getting SLAMF7 activated. We now calculate the slope of the diagonal lines passing through each point with a linear model where the y-intercept for each line is the model coefficient. To identify the points on either extreme of these lines, we calculated and used the corresponding residuals. This approach was performed only for cell types with considerable levels of SLAMF7 expression (i.e., not CD4+ T cells and B cells, which express SLAMF7 at very low levels).

iEN machine learning analysis of tumor response to Ad-SF7-Fc

We first separated mice inoculated with B16 tumors and treated with Ad-SF7-Fc into those who responded and those who did not based on final tumor volume at time of sacrifice (Figure 8A). Next, we pooled together all immune measurements made on these mice across various assays. We then generated a table containing prior immunological knowledge about known responses to adenovirus vectors and expected marker expression across different cell types (other immune measurements were not weighted in our priors so as to not bias the algorithm) (Table S1). We input all immune measurements into the iEN algorithm along with our priors and perform 10-fold cross-validation. Model validation was performed by calculating the area under the receiver operating curve. Networks were generated as previously described. Briefly, each node is a feature entered into the iEN model and node sizes are scaled by their individual area under the receiver operating curve. Edges are significant spearman correlations between features (p < 0.05) after Bonferroni correction for multiple comparisons. Embedding in two-dimensional space was performed with t-distributed stochastic neighbor embedding.

Statistical analysis

Data in all graphs are presented as mean ± standard error of the mean. Statistical analyses are listed in all figure legends and were performed in either GraphPad Prism V8 or the R computing environment. Cell subset frequency comparisons and differential marker expression on cell subsets from experiments using high dimensional spectral cytometry were statistically compared with a generalized linear mixed model implemented through the diffcyt R package. All heatmaps were locally scaled. No samples/mice were excluded from any analysis except for one Ad-null treated WT and one Ad-SF7-Fc treated WT mouse from the same B16 tumor growth experiment, where an outlier test identified the tumor volume in each mouse as a statistically significant outlier.

DATA AND CODE AVAILABILITY

Raw data are available from the authors upon reasonable request.

Code used for all computational analyses can be found at: https://github.com/poconnel3/OConnell_et_al_Ad-SF7-Fc_paper_code.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.omto.2021.12.004.

ACKNOWLEDGMENTS

We would like to thank the MSU genomics core for assistance with qRT-PCR and the MSU histology core for sample preparation and immunohistochemistry. We also thank Dr. David L. Carlson for assistance with SF7-Fc prediction analysis and Anthony Culos for assistance analyzing iEN models. The data presented herein were obtained using instrumentation in the MSU Flow Cytometry Core Facility with support of Core staff. The facility is funded through user fees and the financial support of Michigan State University’s Office of Research & Innovation, College of Osteopathic Medicine, and College of Human Medicine. Y.A.A. and A.A. hold a patent on the SF7-Fc protein. Y.A.A. was supported by the US National Institute of Health grant (1R21AI122808-01) and the Michigan State University Clinical and Translational Sciences Institute (MSU-CTSI). A.A. is supported by the MSU Foundation and the Osteopathic Heritage Foundation.
P.O. is supported by the John A. Penner Endowed Research Fellowship.

AUTHOR CONTRIBUTIONS

P.O. designed all B16 and some CT26 experiments and Y.P. designed some CT26 experiments. P.O., M.K.B., Y.P., and S.H. performed all experiments. M.K.B. performed all bioplex assays. Y.P. analyzed all some CT26 experiments. P.O., M.K.B., Y.P., and S.H. performed all high dimensional single-cell spectral cytometry and analyzed all associated data. P.O. conceptualized and performed all computational analyses. P.O. generated all performed IHC analysis. P.O. performed all high dimensional single-cell vectorized Ad-SF7-Fc and Ad-EAT-2 and designed the vectors. A.M.A. prepared all adenoviruses. S.G. managed all mouse work. Y.A.A. conceived experiments. M.K.B. performed all bioplex assays. Y.P. analyzed all experiments. M.K.B. performed all B16 and some CT26 experiments and Y.P. designed some CT26 experiments. 10. O. is supported by the John A. Penner Endowed Research Fellowship.

REFERENCES

1. Murciano-Goroff, Y.R., Warner, A.B., and Wolchok, J.D. (2020). The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 30, 507–519. https://doi.org/10.4155/cr.20-0337-2.
2. Waldman, A.D., Fritz, J.M., and Lenardo, M.J. (2020). A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668. https://doi.org/10.1038/s41577-020-0306-5.
3. Young, A., Quandt, Z., and Bluestone, J.A. (2018). The balancing act between cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol. Res. 6, 1445–1452. https://doi.org/10.1158/2326-6066.CIR-18-0487.
4. Barrueco, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., and Deshmukh, R.R. (2020). Resistance to checkpoint inhibition in cancer immunotherapy. Transl. Oncol. 13, 100738. https://doi.org/10.1016/j.tranon.2019.12.010.
5. Soldatos, T.G., Dimitrakopoulos, L., Larribera, I., Hassel, J.C., and Sachpekisid, C. (2018). Retroviral side effect profiling of the metastatic melanoma combination therapy ipilimumab-nivolumab using adverse event data. Diagnostics 8. https://doi.org/10.3390/diagnostics8040076.
6. Morse, M.A., Chaudhry, A., Gabitzsch, E.S., Hoebeke, A.C., Osada, T., Clay, T.M., Amal, A., Burnett, B.K., Devi, G.R., Hsu, D.S., et al. (2013). Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol. Immunother. 62, 1293–1301. https://doi.org/10.1007/s00262-013-1400-3.
7. Shaw, A.R., and Suzuki, M. (2019). Immunology of adenovirus vectors in cancer therapy. Mol. Ther. Methods Clin. Dev. 15, 418–429. https://doi.org/10.1016/j.omtm.2019.11.001.
8. O’Connell, P., Popelayevaya, Y., Blake, M.K., Hyslop, S., Crawford, R.B., Rizzo, M.D., Pereira-Hicks, C., Godbehere, S., Cavo, M., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Fallahzadeh, R., Falla
28. Tague, S., Burkhard, S.H., Obs, I., Vroblings, M., Nussbaum, K., Vom Berg, J., Kulig, P., and Becher, B. (2015). New insights into IL-12-mediated tumor suppression. Cell Death Differ. 22, 237–246. https://doi.org/10.1038/cdd.2014.134.

29. Fuertes, M.B., Woo, S.R., Burnett, B., Fu, Y.X., and Gajewski, T.F. (2013). Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34, 67–73. https://doi.org/10.1016/j.it.2012.10.004.

30. Musella, M., Manic, G., De Maria, R., Vitale, I., and Sistigu, A. (2017). Type-I-interferons in infection and cancer: unanticipated dynamics with therapeutic implications. Oncoimmunology 6, e1314424. https://doi.org/10.1080/2162402X.2017.1314424.

31. Way, S.S., Havenar-Daughton, C., Kolumam, G.A., Orgun, N.N., and Murali-Krishna, K. (2007). IL-12 and type-I IFN synergize for IFN-gamma production by CD4 T cells, whereas neither are required for IFN-gamma production by CD8 T cells after Listeria monocytogenes infection. J. Immunol. 178, 4498–4505. https://doi.org/10.4049/jimmunol.178.7.4498.

32. Tugues, S., Burkhard, S.H., Ohs, I., Vrohlings, M., Nussbaum, K., Vom Berg, J., Kulig, P., and Becher, B. (2015). New insights into IL-12-mediated tumor suppression. Cell Death Differ. 22, 237–246. https://doi.org/10.1038/cdd.2014.134.

33. Chevrier, S., Levine, J.H., Zanotelli, V.R.T., Silina, K., Schulz, D., Bacac, M., Ries, C.H., Ailles, L., Jewett, M.A.S., Moch, H., et al. (2017). An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749.e18. https://doi.org/10.1016/j.cell.2017.04.016.

34. Fitzgerald-Bocarsly, P., Dai, J., and Singh, S. (2008). Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 19, 3–19. https://doi.org/10.1016/j.cytogfr.2007.10.006.

35. Quatrini, L., Martotti, F.R., Munari, E., Tumino, N., Vaccia, P., and Moretta, L. (2020). The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy. Cancers (Basel) 12. https://doi.org/10.3390/cancers12113285.

36. Jager, L., Hausl, M.A., Rauschhuber, C., Wolf, N.M., Kay, M.A., and Ehrhardt, A. (2007). IL-12 potentiates CD4(+) T cell and dendritic cell responses to Listeria monocytogenes. J. Immunol. 178, 4498–4505. https://doi.org/10.4049/jimmunol.178.7.4498.

37. Jager, L., Hausl, M.A., Rauschhuber, C., Wolf, N.M., Kay, M.A., and Ehrhardt, A. (2007). IL-12 potentiates CD4(+) T cell and dendritic cell responses to Listeria monocytogenes. J. Immunol. 178, 4498–4505. https://doi.org/10.4049/jimmunol.178.7.4498.

38. Herr, W., Ranieri, E., Olson, W., Zarour, H., Gesualdo, L., and Storkus, W.J. (2000). Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 96, 1857–1864.

39. Alyaqoub, F.S., Aldhamen, Y.A., Koestler, B.J., Bruger, E.L., Sereg, S.S., Pereira-Hicks, C., Godbehere, S., Waters, C.M., and Amaltilano, A. (2016). In vivo Synthesis of cyclic-di-GMP using a recombinant adenovirus preferentially improves adaptive immune responses against extracellular antigens. J. Immunol. https://doi.org/10.4049/jimmunol.1501272.

40. Herr, W., Ranieri, E., Olson, W., Zarour, H., Gesualdo, L., and Storkus, W.J. (2000). Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 96, 1857–1864.

41. Chevrier, S., Crowell, H.L., Zanotelli, V.R.T., Engler, S., Robinson, M.D., and Bodenmiller, B. (2018). Compensation of signal spillover in suspension and imaging mass cytometry. Cell Syst. 6, 612–620.e5. https://doi.org/10.1016/j.cels.2018.02.010.

42. DeTomaso, D., Jones, M.G., Subramaniam, M., Ashuach, T., Ye, C.J., and Yousef, N. (2019). Functional interpretation of single cell similarity maps. Nat. Commun. 10, 4376. https://doi.org/10.1038/s41467-019-12235-0.

43. Quatrini, L., Martotti, F.R., Munari, E., Tumino, N., Vaccia, P., and Moretta, L. (2020). The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy. Cancers (Basel) 12. https://doi.org/10.3390/cancers12113285.

44. Seregin, S.S., Aldhamen, Y.A., Kose, A.S., Koestler, B.J., Bruger, E.L., Sereg, S.S., Pereira-Hicks, C., Godbehere, S., Waters, C.M., and Amaltilano, A. (2016). In vivo Synthesis of cyclic-di-GMP using a recombinant adenovirus preferentially improves adaptive immune responses against extracellular antigens. J. Immunol. https://doi.org/10.4049/jimmunol.1501272.

45. Chevrier, S., Crowell, H.L., Zanotelli, V.R.T., Engler, S., Robinson, M.D., and Bodenmiller, B. (2018). Compensation of signal spillover in suspension and imaging mass cytometry. Cell Syst. 6, 612–620.e5. https://doi.org/10.1016/j.cels.2018.02.010.

46. Sereg, S.S., Aldhamen, Y.A., Kose, A.S., Koestler, B.J., Bruger, E.L., Sereg, S.S., Pereira-Hicks, C., Godbehere, S., Waters, C.M., and Amaltilano, A. (2016). In vivo Synthesis of cyclic-di-GMP using a recombinant adenovirus preferentially improves adaptive immune responses against extracellular antigens. J. Immunol. https://doi.org/10.4049/jimmunol.1501272.